FASTKD1 as a diagnostic and prognostic biomarker for STAD: Insights into m6A modification and immune infiltration

被引:1
|
作者
Yang, Yi [1 ]
Gao, Yan [1 ,2 ,3 ,4 ]
Liu, Xu-Sheng [1 ]
Huang, Zhong-Min [5 ]
Zhang, Yu [1 ]
Zhang, Yao-Hua [1 ]
Liu, Zi-Yue [1 ]
Chen, Yu-Xuan [1 ]
Pei, Zhi-Jun [1 ,2 ,3 ,4 ]
机构
[1] Hubei Univ Med, Taihe Hosp, Dept Nucl Med, 32 Renmin South Rd, Shiyan 442000, Hubei, Peoples R China
[2] Hubei Key Lab Embryon Stem Cell Res, Shiyan 442000, Hubei, Peoples R China
[3] Hubei Univ Med, Taihe Hosp, Hubei Prov Clin Res Ctr Umbil Cord Blood Hematopoi, Shiyan 442000, Hubei, Peoples R China
[4] Hubei Univ Med, Taihe Hosp, Hubei Prov Clin Res Ctr Precis Diag & Treatment Li, Shiyan 442000, Hubei, Peoples R China
[5] Hubei Univ Med, Taihe Hosp, Dept Med Ultrasound, Shiyan 442000, Hubei, Peoples R China
关键词
Fas-activated serine/threonine kinase domain 1; stomach adenocarcinoma; diagnostic and prognostic biomarker; immune infiltration; m6A modification; GENE-EXPRESSION; RNA; CARCINOMA; SURVIVAL; FAMILY;
D O I
10.3892/etm.2024.12594
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Fas-activated serine/threonine kinase domain 1 (FASTKD1), a known modulator of mitochondrial-mediated cell death and survival processes, has garnered attention for its potential role in various biological contexts. However, its involvement in gastric cancer remains unclear. Thus, the present study aimed to investigate the relationship between FASTKD1 expression and key factors, including clinicopathological characteristics, immune infiltration and m6A modification in stomach adenocarcinoma (STAD). The expression of FASTKD1 was analyzed in STAD and normal adjacent tissues to assess its association with clinicopathological characteristics and survival prognosis. Data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases were used in this study. Additionally, the findings were validated through immunohistochemical staining. Co-expression analysis of FASTKD1 was performed using Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (GO/KEGG) enrichment analysis, Gene Set Enrichment Analysis (GSEA) and LinkedOmics database analysis. An in-depth analysis was conducted using databases, such as Tumor Immune Estimation Resource (TIMER), Gene Expression Profiling Interactive Analysis (GEPIA), GEO and TCGA to explore the potential correlation between FASTKD1 expression and immune infiltration and m6A modification in STAD. The results revealed that FASTKD1 was significantly upregulated across different tumor types, including STAD. Notably, FASTKD1 was able to distinguish between tumor and normal tissue samples with accuracy. Furthermore, the expression levels of FASTKD1 were significantly associated with clinical stage and survival. Through GO/KEGG enrichment analysis and GSEA, it was revealed that the genes co-expressed with FASTKD1 were active in a variety of biological processes. Within the TIMER, GEPIA and TCGA databases, a notable inverse correlation was observed between FASTKD1 expression and the abundance of immune cell subsets. Notably, significant correlations were established between FASTKD1 and m6A modification genes, YTHDF1 and LRPPRC, in both TCGA and GEO datasets. In conclusion, FASTKD1 may serve a significant role in m6A modification and immune infiltration processes, making it a potentially valuable diagnostic and prognostic biomarker in STAD.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis
    Liu, Xu-Sheng
    Zhou, Lu-Meng
    Yuan, Ling-Ling
    Gao, Yan
    Kui, Xue-Yan
    Liu, Xiao-Yu
    Pei, Zhi-Jun
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [2] NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis
    Liu, Xu-Sheng
    Zhou, Lu-Meng
    Yuan, Ling-Ling
    Gao, Yan
    Kui, Xue-Yan
    Liu, Xiao-Yu
    Pei, Zhi-Jun
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [3] Identification of KRBA1 as a Potential Prognostic Biomarker Associated with Immune Infiltration and m6A Modification in Hepatocellular Carcinoma
    Liu, Yue
    Fu, Bidong
    Yu, Zichuan
    Song, Gelin
    Zeng, Hong
    Gong, Yiyang
    Ding, Yongqi
    Huang, Da
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2022, 9 : 497 - 516
  • [4] Lactate dehydrogenase A is a diagnostic biomarker associated with immune infiltration, m6A modification and ferroptosis in endometrial cancer
    Huang, Yan
    Tang, Weichun
    Chen, Liping
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [5] ECE2 is a prognostic biomarker associated with m6A modification and involved in immune infiltration of lung adenocarcinoma
    Zhang, Yao-Hua
    Zeng, Jing
    Liu, Xu-Sheng
    Gao, Yan
    Kui, Xue-Yan
    Liu, Xiao-Yu
    Zhang, Yu
    Pei, Zhi-Jun
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [6] SLC2A1 is a Diagnostic Biomarker Involved in Immune Infiltration of Colorectal Cancer and Associated With m6A Modification and ceRNA
    Liu, Xu-Sheng
    Yang, Jian-Wei
    Zeng, Jing
    Chen, Xue-Qin
    Gao, Yan
    Kui, Xue-Yan
    Liu, Xiao-Yu
    Zhang, Yu
    Zhang, Yao-Hua
    Pei, Zhi-Jun
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 10
  • [7] FAM136A as a Diagnostic Biomarker in Esophageal Cancer: Insights into Immune Infiltration, m6A Modification, Alternative Splicing, Cuproptosis, and the ceRNA Network
    Sun, Shaowu
    Huang, Chunyao
    Fan, Wenbo
    Wang, Zhulin
    Li, Kaiyuan
    Liu, Xu
    Wang, Zelong
    Zhao, Tianliang
    Zhang, Guoqing
    Li, Xiangnan
    ADVANCED BIOLOGY, 2024, 8 (11):
  • [8] SOX11 as a prognostic biomarker linked to m6A modification and immune infiltration in renal clear cell carcinoma
    Wang, Kaihong
    Chen, Xinpeng
    Liu, Yifu
    Meng, Xuan
    Zhou, Libo
    TRANSLATIONAL CANCER RESEARCH, 2024, 13 (07)
  • [9] LDHA is a prognostic biomarker on the immune response in pancreatic adenocarcinoma and associated with m6A modification
    Zhen Tan
    Jiang Liu
    Jin Xu
    Bo Zhang
    Xianjun Yu
    Wei Wang
    Chen Liang
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 4853 - 4865
  • [10] LDHA is a prognostic biomarker on the immune response in pancreatic adenocarcinoma and associated with m6A modification
    Tan, Zhen
    Liu, Jiang
    Xu, Jin
    Zhang, Bo
    Yu, Xianjun
    Wang, Wei
    Liang, Chen
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (08) : 4853 - 4865